We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Found for Epithelial Cancer Stem Cells

By LabMedica International staff writers
Posted on 19 Oct 2014
Tumors are mosaics of cells that are morphologically and molecularly very different and over the past years have been suggested to be responsible for the origin of cancer and for the resistance to conventional chemical therapies.

Cancer stem cells (CSCs) are thought to drive tumor growth, metastasis and chemoresistance but as there are only a small percentage of cancer stem cells in a solid tumor, this makes it difficult to isolate and analyze them, as well as to study the origin of drug resistance. More...


Scientists at the Spanish National Cancer Research Center (Madrid, Spain) identified cells with an autofluorescent subcellular compartment that exclusively showed CSC features across different human tumor types. Primary tumor–derived autofluorescent cells did not overlap with side-population (SP) cells, were enriched in sphere culture and during chemotherapy, strongly expressed pluripotency-associated genes, were highly metastatic and showed long-term in vivo tumorigenicity, even at the single-cell level.

Autofluorescence was due to riboflavin accumulation in membrane-bounded cytoplasmic structures bearing adenosine triphosphate (ATP)-dependent ATP-binding cassette sub-family G member 2 (ABCG2) transporters. The team was able to characterize an intrinsic autofluorescent phenotype in CSCs of diverse epithelial cancers and used this marker to isolate and characterize these cells. Riboflavin is a pigment that emits green fluorescence as a result of its accumulation inside intracellular vesicles. This light emission property, acts to track, isolate, and later purify it, without the need for antibodies or other more costly and complex techniques. The discovery was carried out in several types of tumors, including samples from patients with pancreas, liver, colon and lung cancer.

Christopher Heeschen MD, PhD, the senior author of the study said, “The discovery of this new marker is a breakthrough, as it can select for tumor stem cells, which are the most invasive and chemical-resistant cancer cells. Autofluorescence allows these cells to be tracked in an easy, simple and inexpensive way, as well as to study the origin of the tumor’s chemical resistance.” The study was published on September 28, 2014, in the journal Nature Medicine.

Related Links:
Spanish National Cancer Research Center 



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.